Capsid-targeted viral inactivation can destroy dengue 2 virus from within in vitro.
Capsid-targeted viral inactivation (CTVI) has emerged as a conceptually powerful antiviral strategy that exploits viral structural proteins to target a destructive enzyme specifically into progeny virions. We have recently demonstrated the principle of CTVI against dengue virus infection and observed a modest therapeutic effect in vitro (Arch Virol 2005, 150: 659-669). Here we tested a prophylactic model of CTVI, in which mammalian cells stably expressing the dengue 2 virus capsid protein fused to a nuclease were infected with dengue virus and determined the effects on progeny virion infectivity. CTVI efficiently destroyed dengue 2 virus from within and decreased the infectious titers by 10(3)- to 10(4)-fold, suggesting that CTVI has potential in the prophylactic application for dengue virus infection.
Qin
C-F
CF
State Key Laboratory of Pathogen and Biosecurity, Beijing, P.R. China.
Qin
E-D
ED
D000818:Animals; D036022:Capsid Proteins / Q000235:genetics* / Q000378:metabolism*; D002460:Cell Line; D006224:Cricetinae; D003715:Dengue / Q000628:therapy* / Q000821:virology*; D003716:Dengue Virus / Q000235:genetics / Q000254:growth & development / Q000378:metabolism*; D004720:Endonucleases / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D005814:Genes, Viral; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D019065:Virus Assembly; D038301:Virus Inactivation
D036022:Capsid Proteins; D011993:Recombinant Fusion Proteins; D004720:Endonucleases